<DOC>
	<DOCNO>NCT00112645</DOCNO>
	<brief_summary>RATIONALE : A peripheral stem cell , bone marrow , umbilical cord blood transplant may able replace blood-forming cell destroy chemotherapy radiation therapy . Sometimes transplanted cell donor make immune response body 's normal cell . Giving busulfan melphalan without antithymocyte globulin transplant cyclosporine methylprednisolone methotrexate transplant may stop happen . PURPOSE : This phase I trial study side effect donor stem cell transplant treat young patient relapsed refractory solid tumor .</brief_summary>
	<brief_title>Donor Stem Cell Transplant Treating Young Patients With Relapsed Refractory Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine toxicity allogeneic hematopoietic stem cell transplantation , term incidence grade 3-4 acute graft-versus-host disease , young patient relapsed refractory solid tumor . - Determine incidence transplant-related mortality 100 day post-transplantation patient . OUTLINE : - Conditioning : Patients receive busulfan IV orally 4 time daily day -8 -5 ( total 16 dos ) melphalan IV 15-20 minute day -4 -2 . Patients unrelated donor also receive anti-thymocyte globulin IV day -4 -2 . - Allogeneic hematopoietic stem cell transplantation ( SCT ) : Patients undergo allogeneic hematopoietic SCT day 0 . - Post-transplant graft-versus-host disease ( GVHD ) prophylaxis : Patients undergo cord blood SCT receive cyclosporine methylprednisolone graft-versus-host disease ( GVHD ) prophylaxis . Patients undergo peripheral blood bone marrow SCT receive cyclosporine methotrexate ( short course ) GVHD prophylaxis . After completion study treatment , patient follow 1 , 3 , 6 , 12 month annually thereafter . PROJECTED ACCRUAL : A total 10 patient accrue study within 4 year .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis relapse refractory solid tumor , include , limited , relapsed neuroblastoma , relapse Ewing 's sarcoma , relapse rhabdomyosarcoma No isolate local disease recurrence site primary tumor &gt; 1 year completion prior therapy No brain tumor brain metastasis Related unrelated hematopoietic stem cell donor available , meet 1 follow criterion : Matched HLAA , B , C , DR , DQ ( 9/10 10/10 allelles ) ( marrow peripheral blood ) Matched HLAA , B , DR ( 5/6 6/6 allelles ) ( cord blood ) Cord blood specimen must contain ≥ 2 x 10 ^7 nucleate cells/kg body weight PATIENT CHARACTERISTICS : Age 30 Performance status ECOG 01 OR Lansky 80100 % Life expectancy Not specify Hematopoietic Not specify Hepatic Bilirubin ≤ 3.0 mg/dL Renal Creatinine clearance ≥ 50 mL/min Cardiovascular Ejection fraction ≥ 50 % Pulmonary DLCO ≥ 70 % OR O_2 saturation ≥ 95 % room air Other Not pregnant Negative pregnancy test Fertile patient must use effective contraception HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy Prior autologous stem cell transplantation allow Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>unspecified childhood solid tumor , protocol specific</keyword>
	<keyword>recurrent neuroblastoma</keyword>
	<keyword>recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>recurrent childhood rhabdomyosarcoma</keyword>
</DOC>